[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse BIN1

Summary
SymbolBIN1
Namebridging integrator 1
Aliases SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location2q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform BIN1: Nucleus.; SUBCELLULAR LOCATION: Isoform IIA: Cytoplasm.
Domain PF03114 BAR domain
PF14604 Variant SH3 domain
Function

May be involved in regulation of synaptic vesicle endocytosis. May act as a tumor suppressor and inhibits malignant cell transformation.

> Gene Ontology
 
Biological Process GO:0006997 nucleus organization
GO:0007050 cell cycle arrest
GO:0010001 glial cell differentiation
GO:0010720 positive regulation of cell development
GO:0014013 regulation of gliogenesis
GO:0014015 positive regulation of gliogenesis
GO:0030100 regulation of endocytosis
GO:0042063 gliogenesis
GO:0042692 muscle cell differentiation
GO:0045685 regulation of glial cell differentiation
GO:0045687 positive regulation of glial cell differentiation
GO:0045786 negative regulation of cell cycle
GO:0048708 astrocyte differentiation
GO:0048710 regulation of astrocyte differentiation
GO:0048711 positive regulation of astrocyte differentiation
GO:0050769 positive regulation of neurogenesis
GO:0051640 organelle localization
GO:0051647 nucleus localization
GO:0051962 positive regulation of nervous system development
GO:0060627 regulation of vesicle-mediated transport
GO:0060988 lipid tube assembly
GO:0065005 protein-lipid complex assembly
GO:0071156 regulation of cell cycle arrest
GO:0071825 protein-lipid complex subunit organization
Molecular Function GO:0003779 actin binding
GO:0048156 tau protein binding
GO:0051015 actin filament binding
GO:0070063 RNA polymerase binding
Cellular Component GO:0005635 nuclear envelope
GO:0015629 actin cytoskeleton
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0030018 Z disc
GO:0030315 T-tubule
GO:0030424 axon
GO:0031674 I band
GO:0032994 protein-lipid complex
GO:0033267 axon part
GO:0033268 node of Ranvier
GO:0042383 sarcolemma
GO:0043194 axon initial segment
GO:0043292 contractile fiber
GO:0044304 main axon
GO:0044449 contractile fiber part
GO:0060987 lipid tube
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
hsa04666 Fc gamma R-mediated phagocytosis
Reactome R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-199991: Membrane Trafficking
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolBIN1
Namebridging integrator 1
Aliases SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location2q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BIN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BIN1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28714960Non-small cell lung carcinomaPromote immunity (infiltration and T cell function)BIN1 is frequently attenuated or even silenced in human tumors including melanoma, breast, prostate, bladder and lung cancers. In the present study, we observed that there exists a negative correlation between the expression of PD-L1 and BIN1 in NSCLC tissues. The expression levels of BIN1 and PD-L1 were significantly related to the tumor, lymph node and metastasis grade (TNM) stage, invasion range and lymph node metastasis. Simultaneously, for NSCLC patients, the expression statuses of BIN1 and PD-L1 might be independent prognostic factors. Furthermore, the expression of tumor-infiltrating lymphocytes was positively associated with BIN1 expression and negatively related to PD-L1 expression in NSCLC tissues. Importantly, we showed that PD-L1 was under the control of BIN1. Bridging integrator-1 (BIN1) is a MYC-interacting adaptor protein that has features of a tumor suppressor. In addition, the overexpression of BIN1 could inhibit the c-MYC and epithelial growth factor receptor (EGFR)-dependent PD-L1 expression and reverse the suppressive immuno-microenvironment in vivo.
Summary
SymbolBIN1
Namebridging integrator 1
Aliases SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location2q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BIN1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBIN1
Namebridging integrator 1
Aliases SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location2q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BIN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6610.12
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6310.722
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6980.651
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1510.764
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0240.991
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3720.89
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0530.885
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1460.906
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0220.988
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.520.744
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3570.877
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3030.0774
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BIN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBIN1
Namebridging integrator 1
Aliases SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location2q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BIN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBIN1
Namebridging integrator 1
Aliases SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location2q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BIN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BIN1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBIN1
Namebridging integrator 1
Aliases SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location2q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BIN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBIN1
Namebridging integrator 1
Aliases SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location2q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BIN1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBIN1
Namebridging integrator 1
Aliases SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location2q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BIN1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBIN1
Namebridging integrator 1
Aliases SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location2q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BIN1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.